搜尋結果
Eisai defines epilepsy as a therapeutic area of focus. As of July 2013, the company’s in-house-developed AMPA receptor antagonist Fycompa® (perampanel) has been approved as a novel treatment for partial seizures in over 30 countries, including the United States and in Europe, having been launched in various EU member states since September 2012.
2008年5月29日 · GlaxoSmithKline K.K. (Head Office: Tokyo, President: Marc Dunoyer) and Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announce that they have agreed to terminate their alliance to market Breathe Right ® nasal strips, manufactured by GlaxoSmithKline group and marketed in Japan by Eisai, as of 31 May 2008.
Eisai defines epilepsy as a therapeutic area of focus. As of October 2013, the company’s in-house-developed AMPA receptor antagonist Fycompa® (perampanel) has been approved as a novel treatment for partial seizures in over 30 countries, including the United States and in Europe, having been launched in various EU member states since September 2012.
2018年7月18日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it has obtained the topline results of the ongoing Cardiovascular Outcomes Trial (“CAMELLIA-TIMI61”) of lorcaserin hydrochloride (generic name, product name in the U.S.: BELVIQ ®, “BELVIQ”) in 12,000 patients as a post-marketing clinical ...
